Categories
Business India News

Sputnik vaccine production to slow down amid Ukraine crisis

Meanwhile, the RDIF has said that it and its international partners believe that only diplomacy can end this conflict and save human lives…reports Avinash Prabhakar

The economic sanctions imposed by the US on Russia amid ongoing conflict with Ukraine are expected to slow down the production of Russia’s Sputnik vaccines in India.

The Russian Direct Investment Fund (RDIF), promoter of vaccine, is Russia’s sovereign wealth fund and investor in Sputnik coronavirus vaccines, is among the sanctioned.

India is the second-largest manufacturer of vaccines after Russia and also the largest market for vaccines. The RDIF has partnered with Serum Institute of India, Gland Pharma, Hetero Biopharma, and other Indian pharmaceutical companies to manufacture vaccines in India.

Indian companies had planned to produce at least 1,152 million doses of Sputnik V per year. However, the blocking of certain Russian banks’ access to the SWIFT international payment system may hamper the process of payments which, in turn, can lower down the production in India.

Meanwhile, the RDIF has said that it and its international partners believe that only diplomacy can end this conflict and save human lives.

“From day one, the Russian Direct Investment Fund has been focused on people and improving their quality of life. RDIF helped protect millions of people in over 70 countries through its humanitarian mission to fight coronavirus infection. RDIF supports restoration of peace and hopes negotiations between representatives of Russia and Ukraine are successful. RDIF and its international partners believe that only diplomacy can end this conflict and save human lives,” it said.

“Sputnik is manufactured in India by Hetero and Serum Institute of India and distributed by Dr. Reddy’s Labs. So the supply across India should not suffer. However the sale so far has been very modest (just 1.2 million out of the 1.8 billion doses of vaccine administered so far). How the sanctions will impact Sputnik’s sales in 29 countries where it has been approved is yet to be seen. The approvals from WHO for Sputnik V will surely take longer or even may not come depending on how strongly does WHO come down on the invasion,” Pavan Choudary, Chairman, Medical Technology Association of India (MTaI) told.

ALSO READ-Priyanka calls Ukraine-Russia conflict as ‘terrifying’

Categories
-Top News COVID-19 UAE News

UAE approves Pfizer, Sputnik booster shots for over-60s

The UAE health sector plays a fundamental role in strengthening the national response to the COVID-19 pandemic and stemming its consequences…reports Asian Lite News

The Ministry of Health and Prevention (MoHAP) has launched a protocol for providing booster shots of the Pfizer-BioNTech and Sputnik V vaccines approved for emergency use, as part of the national vaccination campaign efforts, announced Dr. Noura Al Ghaithi, Official Spokesperson of the UAE Health Sector.

During the UAE Government media briefing on the COVID-19 pandemic, Dr. Al Ghaithi said that the UAE health sector plays a fundamental role in strengthening the national response to the COVID-19 pandemic and stemming its consequences.

“We are proud of this proactive approach and of being one of the first countries to turn the challenges of the COVID-19 pandemic into opportunities and benefit from all the experiences we have gone through to become a global model,” Dr. Al Ghaithi added.

The health sector has invested in its R&D potential and capabilities to realise the goals we’ve have achieved today, most notably safe vaccines in addition to the efficient treatment protocol in our hospitals, she continued.

“The health sector is continuing to achieve acquired immunity by providing COVID-19 vaccines to eligible people. Nearly 94.78 percent of the population have taken their first vaccine dose, while 84.3 percent are now fully vaccinated.”

ALSO READ: 40% of UP is now Covid free

Dr. Al Ghaithi explained that the groups that should take the booster dose are senior citizens; residents above 60 years; people with chronic diseases; individuals at risk of complications from 50 to 59 years old, and people receiving long-term health care aged 18 and above.

Al Ghaithi said the protocol does not apply to the groups who have received Pfizer-BioNTech or Sputnik V booster doses after being fully vaccinated with Sinopharm.

“We recommend individuals who are eligible for the booster shot be sure to take this dose on time, to protect their health and ensure safety from COVID-19 by boosting their immunity,” she added. “The UAE has achieved a leading position, both regionally and globally, in terms of how it handled the pandemic, due to the cooperation of various sectors that helped achieve strategic balance and sustainable recovery.”

She further added that these impressive successes have been achieved thanks to the forward-looking vision of the wise leadership and the commitment and awareness of the UAE community, which will help restore normalcy soon.

At the end of the briefing, Dr. Al Ghaithi highlighted the need for social cohesion at this current stage to maintain all the gains achieved. “The phased removal of restrictions we are witnessing now requires all of us to share social responsibility to ensure public health and safety, contain the pandemic, and move towards a brighter future,” she said, in conclusion.

Categories
-Top News Asia News India News

Citing wastage, Russia urges India to lift ban on vaccine export

He has requested the Indian government to allow the export of Sputnik Light to his country till the vaccine gets emergency use authorisation from India’s drug regulator…reports Asian Lite News.

Russia has sought a nod from the Indian government to lift a ban on the export of single-dose Covid vaccine Sputnik Light citing the reason for its shelf life and possibility of being wasted.

The Sputnik Light vaccine in India is produced by Hetero Biopharma which is one of the Russian Direct Investment Fund partners in the production of the vaccine.

“Hetero Biopharma Limited, one of the leading Indian pharmaceutical companies and RDIF’s partner in the production of the Sputnik Light, has already manufactured one million doses of Component I of the Sputnik V vaccine and two million doses of the Sputnik Light and intends to continue its production further,” said Russian ambassador Nicholay Kudashev in a communication to the Centre.

He has requested the Indian government to allow the export of Sputnik Light to his country till the vaccine gets emergency use authorisation from India’s drug regulator.

“However, a shelf life tenure of the vaccine, i.e., six months only, may expire before its registration, which will result in the wastage of several million doses of the vitally important Sputnik Light vaccine”, he added further.

“We would like to note that the Indian manufacturers of the Russian vaccine are discouraged by the current ban that prevents the use of the produced Sputnik Light vaccine in India and its export to other countries,” said the communication to V.K. Paul, chair of the National Expert Group on Vaccine Administration for Covid-19 (NEGVAC).

The ARDIF and Dr Reddy’s Laboratories are working with the authorities on the registration of the Sputnik Light in India.

However, the top source at the Union Health Ministry confirmed that the government has not yet responded to Russia’s request and any decision can be made soon.

Covaxin may get WHO approval by month-end

Meanwhile, India’s indigenously-developed Covid vaccine Covaxin may soon receive Emergency Use Listing by the World Health Organisation, eventually enabling its recipients to travel abroad without mandatory quarantine, NITI Aayog’s Member, Health, V.K. Paul said on Wednesday.

Data sharing and data evaluation are going on and a positive decision may come soon, he said.

“The data sharing and data evaluation have been going on through multiple reviews and we are close to a decision point.

“We must give time to WHO to make their decisions based on science. However, we hope that these decisions can be taken quickly because people who are receiving Covaxin have certain imperatives of travel. Most of us, who chose the concurrency, is important in terms of licensure. We are hoping for an early decision,” Dr Paul said.

https://www.youtube.com/watch?v=Axhr4rpcv30

“We believe that a positive decision could be coming in, before the end of the month,” he added.

In August, Indian Health Minister Mansukh Mandaviya also met WHO Chief Scientist Dr Soumya Swaminathan and held discussions over the WHO approval of Covaxin.

The vaccine’s developer Bharat Biotech has submitted its Phase 3 clinical trials data that demonstrated 77.8 per cent efficacy to the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).

The WHO has so far approved Covid-19 vaccines by Pfizer-BioNTech, AstraZeneca, Johnson and Johnson, Moderna, and Sinopharm.

Delhi reports a Covid death after 8 days

The national capital on Thursday reported a Covid death after eight days, as well as 28 fresh cases.

With the new cases and fatality, the case tally has gone up to 14,38,373, and the death toll to 25,084, according to the Delhi Health Department bulletin.

The number of active cases stand at 409, of which 110 are being treated in home isolation.

A total of 22 Covid patients were discharged in the last 24 hours, taking the total number of recoveries to 14,12,880, the bulletin said.

According to the bulletin, the city has reported slight surge in Covid infection rate which currently stands at 0.028 per cent, while the recovery rate continues to be at 98.22 per cent, and the death rate 1.74 per cent.

Delhi has a total 94 containment zones currently.

A total of 72,481 new tests – 49,734 RT-PCR and 22,747 Rapid Antigen – wer conducted, taking the total to 2,67,47,181 so far.

A total of 1,37,846 vaccines were administered in the last 24 hours, including 83,096 first doses, and 54,750 second doses.

ALSO READ-UK Begins Covid Booster Vaccine Rollout

READ MORE-95% surge in public trust in UAE’s Covid measures

Categories
-Top News COVID-19 USA

Covaxin, Sputnik V jabs red-flagged in US

Campuses are proposing different measures, out of which the more complicated scenario is if students received a vaccine that has not been approved by the WHO, like Sputnik or Covaxin…reports Asian Lite News

Since March, over 400 US colleges and universities have announced students get Covid-19 vaccinations, ahead of the Autumn semester but those who have been inoculated with India’s indigenous Covaxin or the Russian-made Sputnik V are being asked to re-vaccinate as these vaccines have not yet been approved by the World Health Organisation (WHO).

Rukmini Callimachi reports in the The New York Times that Milloni Doshi, a 25-year-old student from India, who is due to start her master’s degree this fall at Columbia University’s School of International and Public Affairs, has been administered two doses of Covaxin. Now, Columbia has told her that she will need to be revaccinated with a different vaccine once she arrives on campus.

“I am just concerned about taking two different vaccines. They said the application process would be the toughest part of the cycle, but it’s really been all of this that has been uncertain and anxiety-inducing,” Doshi wrote via a messaging app.

Campuses are proposing different measures, out of which the more complicated scenario is if students received a vaccine that has not been approved by the WHO, like Sputnik or Covaxin. Many colleges are proposing that those students will need to be revaccinated, which presents both medical and logistical conundrums.

This is primarily because no data exists on whether combing vaccines from different companies is safe. “Since Covid-19 vaccines are not interchangeable, the safety and effectiveness of receiving two different Covid-19 vaccines have not been studied,” said Kristen Nordlund, spokesperson for the Centers for Disease Control and Prevention (CDC).

Nordlund also advised that people vaccinated outside the US with a vaccine not authorised by WHO should wait for a minimum of 28 days before taking the first dose of one of the Food and Drug Administration (FDA)-sanctioned vaccines.

American students have access to the Pfizer, Moderna and Johnson & Johnson vaccines, three of the eight doses authorised by the global health body. This disparity could hinder colleges that have made it a major priority to retain international students, who brought in close to USD 39 billion in tuition dollars in the year before the pandemic, according to an analysis.

ALSO READ: BRICS Backs Covid-19 Vaccine Patent Waivers

“Universities want to enroll international students because they add diversity to the campus community — and they bring money… It’s why this has been a subject of intense discussion,” said Terry W Hartle, senior vice president at the American Council on Education.

According to The New York Times, the situation is particularly challenging for students from India, which sends around 200,000 international students to American colleges every year. It is becoming increasingly hard to secure an appointment for a vaccine that will be accepted by American campuses.

“Every day, we get 10 to 15 messages and inquiries, saying ‘What does this mean? How does this impact me?'” said Sudhanshu Kaushik, who runs the North American Association of Indian Students, which is working to help fellow students.

Indiana University’s vice president for international affairs, Hannah Buxbaum, said that the administrators of the institution are working overtime to answer the roughly 200 phone calls and 300 emails that are pouring in every day from the university’s roughly 6,000 students overseas.

“Ringing off the hook doesn’t begin to describe. There is no question that there is anxiety and concern among our international students,” she said.

Many universities are only accepting the students who have been vaccinated with a WHO-approved COVID-19 vaccine. At Columbia, where one-third of the student body is from overseas, international students will be asked to present either their WHO booklet or a letter from a physician confirming they have received the requisite doses of one of the vaccines vetted by the world body, said Donna Lynne, the chief operating officer of the university’s medical centre.

Callimachi writes for The New York Times that those who will not succeed in securing a vaccine before the start of the fall semester are facing a potentially problematic process.

Many universities were vague on how they plan to deal with the logistical complexity of spacing out these unrelated vaccines, beyond saying that they planned to accommodate students undergoing this process, reports The New York Times.

At least six regional governments in India have announced emergency clinics in the past week to vaccine students going to US universities, in wake of mounting pressure from confused and anxious students, wrote Callimachi.

However, Hyderabad-based Bharat Biotech on Thursday said that biopharmaceutical company Ocugen Inc will have exclusive co-development, manufacturing, and commercialisation rights of its COVID-19 vaccine Covaxin in Canada, in addition to its existing United States rights. (ANI)

ALSO READ: Biden announces vaccine sharing plan

Categories
-Top News COVID-19 India News

India gets first consignment of Sputnik vaccine

A special cargo flight carrying the first consignment of Sputnik V vaccine doses landed at Rajiv Gandhi International Airport, reports Asian Lite News

First batch of Russian vaccine for Covid-19, Sputnik V, arrived in Hyderabad on Saturday.

A special cargo flight carrying the first consignment landed at Rajiv Gandhi International Airport.

Sputnik
Russia’s Sputnik-V vaccine arrives in Hyderabad. (Photo: @MEAIndia/Twitter)

It was immediately not clear how many doses have arrived. The consignment was delivered to Dr Reddy’s Laboratories, which has entered into an agreement with the Russian vaccine maker.

The company will seek mandatory approval of Central Drugs Laboratory for distribution of the vaccine in the country.

Also Read: India waives customs duty on oxygen, vaccines

“First batch of Sputnik V has arrived in Hyderabad, India. That’s the same day the country starts mass Covid vaccination drive covering entire adult population. Let’s jointly defeat this pandemic. Together we are stronger,” tweeted Sputnik V.

Russia’s Sputnik-V vaccine arrives in Hyderabad. (Photo: @MEAIndia/Twitter)

Last month, the Indian regulators granted regulatory approval or restricted use authorisation to Sputnik V.

With an efficacy of 91.6 per cent, Sputnik V was the first vaccine against Covid-19 in the world. Clinical trial data published in The Lancet indicated that the vaccine is “appears safe and effective”.

Also Read: B’desh govt nod for emergency use of Russian vaccine

Categories
-Top News Asia News Bangladesh

B’desh okays Russian vaccine Sputnik

The approval comes after Bangladesh health authorities stopped administering Covishield vaccine from India…reports Asian Lite News

The Bangladeshi government has approved the import and use of Russia’s Sputnik V vaccine against Covid-19.

Major General Mahbubur Rahman, Director General of the country’s Drug Administration, made the announcement on Tuesday, the Xinhua news agency reported.

The decision came days after Dhaka suspended the first dosing of the Oxford-AstraZeneca vaccine on a supply crunch.

“We’ve given permission for the emergency use of the Russian Covid-19 vaccine,” Rahman told journalists.

Amid uncertainty over timely arrival of the next Covid-19 vaccine shipment from India, the Bangladeshi government halted administering first dose of the AstraZeneca vaccine across the country from Monday.

Also read:Peaceful Bangladesh a boon for India and South Asia

Nearly 6 million people have so far received the first dose of the vaccine in Bangladesh.

Prime Minister Sheikh Hasina on January 28 virtually inaugurated the country’s Covid-19 vaccination drive.

The Bangladeshi government on Monday announced that it decided to extend the ongoing lockdown which began on April 14 for another week.

Bangladesh recorded 112 deaths from Covid-19 on April 19, its highest daily toll from the pandemic, the government said.

On Tuesday, the country’s Directorate General of Health Services (DGHS) reported 3,031 new cases of Covid-19 and 78 new deaths, bringing the number of total cases to 751,659 and the total death toll to 11,228.

Also read:Entry ban: 250 Bangladeshis stranded at border

Categories
-Top News India News

Third vaccine cleared for emergency use in India

The development has come at a time when India is witnessing an exponential surge in Covid-19 cases and vaccines have been much in demand….reports Asian Lite News

A government expert panel has given its nod to emergency use authorisation of Russian-made Covid vaccine, Sputnik-V, in India, Union Health Ministry sources said.

After the Drug Controller General of India gives assent to the Subject Expert Committee’s approval, the sources said, India will have a third Covid vaccine after AstraZeneca-Oxford University developed-Serum Institute of India-manufactured Covishield and Bharat Biotech-developed and manufactured Covaxin.

Indian Council of Medical Research’s (ICMR) Dr N.K. Arora, talking to IANS, said: “Though, I am yet to receive any official information about its approval, but it would be good news for India if it is approved.”

Explaining features of this vaccine, Arora said: “Sputnik is a two dose vaccine. The composition of the first dose will be different from the second dose and there should be at least a three to four weeks gap between the first dose and the second. The published data suggest that it has 91 per cent efficacy. Some more clarity on it will also come soon.”

The development has come at a time when India is witnessing an exponential surge in Covid-19 cases and vaccines have been much in demand.

A medical health worker giving a shot of Covishield vaccine to a frontline worker. Covid-19 vaccination drive at private hospital daryaganj in New Delhi
Also read:France likely to join Indian Ocean initiative

Meanwhile, amid reports that the subject expert committee (SEC) has approved Dr. Reddy’s Laboratories’ (DRL) application for the Russian vaccine candidate Sputnik V to tackle Coronavirus pandemic, the city-based company is yet to receive official communication about the approval.

“There is no approval received yet. We are still awaiting the statement from the SEC. Once we get something, we will release a statement,” a DRL official said on Monday.

He said that the SEC has to first pass on the recommendation to the Drugs Controller General of India (DCGI) and then the latter has to give the nod.

The pharmaceutical major is expecting that this process might take a day or two.

When quizzed on the company’s preparedness to produce the vaccine in large numbers, the official said ‘we will be releasing details as and when we get some input there (from SEC and DCGI)’.

This development comes at a time when several Indian states are facing severe vaccine shortage and is a positive development.

Meanwhile, Dr. Reddy’s scrip rallied on the bourses, reacting to the approval news reports.

Also read:PM: Martyrs give strength to every Indian

Categories
Africa News

Libya gets 1st Covid vaccine batch

The Sputnik vaccine doses from Russia reached Libyan capital and will be secured in the Health Ministry’s custody…reports Asian Lite News

Libya has received its first shipment of vaccines against Covid-19, with 101,250 doses from Russia, the Health Ministry said on Sunday.

The Sputnik doses arrived in the capital Tripoli and will be stored in the Health Ministry’s warehouses, according to official news agency LNA.

No date has been given for when vaccinations will begin, dpa news agency quoted the LNA as saying.

Interim Prime Minister Abdul-Hamid Mohammed Dbeibeh said on Sunday that more vaccine shipments would follow and called on the public to register in order to receive a jab.

So far, Libyan health authorities have reported a total of 161,088 Covid-19 cases and 2,684 deaths.

Zulema Riquelme, a 46-year-old nursing technician, receives a shot of the COVID-19 vaccine at the Metropolitan Hospital in Santiago, Chile

Last month, a transitional unity government took office in Libya, a major step towards re-establishing stability in the country that has been roiled by conflict for a decade.

The interim government is tasked with preparing for national elections, scheduled for December 24.

This government has replaced the UN-backed Government of National Accord (GNA), which has been in charge of Tripoli and western areas, alongside the competing eastern administration linked with warlord Khalifa Haftar.

Libya plunged into chaos after the fall of late leader Muammar Gaddafi’s government in 2011, witnessing prolonged conflict between the eastern-based Haftar-led Libyan National Army (LNA) and the GNA in the country’s west.

Due to the protracted armed conflict, political and economic crises and the coronavirus pandemic, nearly 1.2 million people, including over 348,000 children, require humanitarian assistance in Libya, according to the Unicef.

Also read:France reopens Libya Embassy